Press Releases

QuidelOrtho Corporation a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026. The LEX VELO System is a breakthrough molecular diagnostics platform that is designed to deliver highly sensitive, multiplex RT-PCR testing

Myomo, Inc.  a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb paralysis, announces the launch of the Myomo® Mobile App, a new digital tool designed to support clinicians and patients throughout the MyoPro® experience. The Myomo Mobile App is designed to make MyoPro care more intuitive, more connected, and more data-informed. For clinicians, the app provides a streamlined mobile interface for cu

The Symbotic System is an AI-powered platform that automates picking, storage and retrieval of items for distribution. Widely used across multiple complex industries, including large scale retail and consumer goods companies, the technology uses intelligent, autonomous robots to depalletize and singulate inbound full pallets, store and retrieve items, and build orders into smart outbound pallets mapped to the needs and layouts of downstream recipients, helping to drive faster and more efficie

Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today highlighted the successful use of the SynCardia Total Artificial Heart (“STAH”) as a bridge to heart transplantation at Texas Children’s Hospital (“Texas Children’s”), supporting a 21-year-old patient thro

Greenspace Health and LifeStream Behavioral Center, a leading nonprofit provider of behavioral health and social services in Central Florida, have partnered to implement Measurement-Based Care (MBC) across LifeStream’s full continuum of programs. The collaboration will leverage data-driven insights and patient-reported outcome measures (PROMs) within the care process to improve service quality and clinical outcomes for thousands of individuals served across Lake, Citrus, Sumter, Orange,

Nano X Imaging Ltd, a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a new distribution agreement with Digital X-Ray Imaging Inc., a leading diagnostic imaging provider serving healthcare facilities across Arkansas. The agreement will support the deployment of the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings at a lower cost a

Etiometry, a leader in AI-driven clinical intelligence, today announced it has received FDA clearance (K254066) for the first-ever solution for automation of hospital-specific cardiogenic shock classification and tracking by directly utilizing data from physiologic monitoring, the Etiometry Cardiogenic Shock Tool. Cardiogenic shock remains a critical challenge, with delayed identification contributing to poor outcomes and persistently high mortality rates, despite advances in care.

Neuropacs™ Corp., an innovator in AI-enabled neurological imaging, today announced that the U.S. Food and Drug Administration has granted De Novo classification to neuropacs™, a diffusion MRI–based software application designed to assist clinicians in the evaluation of Parkinsonian syndromes. neuropacs™ is the first medical device classified by the FDA under the new category of “Parkinsonian syndrome diagnostic aid.” The software analyzes diffusio

Neuropacs™ Corp., an innovator in AI-enabled neurological imaging, today announced that the U.S. Food and Drug Administration has granted De Novo classification to neuropacs™, a diffusion MRI–based software application designed to assist clinicians in the evaluation of Parkinsonian syndromes. neuropacs™ is the first medical device classified by the FDA under the new category of “Parkinsonian syndrome diagnostic aid.” The software analyzes diffusio

Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the enrollment of the first patient in the ALPHA Registry, a prospective, multicenter registry evaluating the safety and effectiveness of the LOBO™ Vascular Occlusion System for patients suffering from a variety of peripheral vascular conditions, including arterial hemorrhage and pulmonary arteriovenous malformation. "We are honored to enroll the first patient in